DPP-4 inhibitors can extend the half-lives of bradykinin and substance P, therefore increasing the risk of hypersensitivity reactions, especially angioedema; which is among the hypersensitivity reactions reported in the prescribing information of most DPP-4 inhibitors as post-marketing events. This evidence concerns the gene DPP4 and angioedema.